Stefan Oschmann, member of the executive board and CEO Pharma at Merck KGaA, has been elected new president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for a two-year term. He succeeds John Lechleiter, chairman, president, and CEO at Eli Lilly & Company.
Based in Geneva, IFPMA engages with the global health community to find effective and sustainable solutions to global health policy issues with a focus on innovation and access to quality pharmaceuticals. IFPMA holds formal consultative status with the United Nations and its specialized agencies, including the World Health Organization and the World Intellectual Property Organization. IFPMA focuses on a wide range of issues, including access to innovation and intellectual property, regulatory frameworks, sustainable health policies, and ethical practices and transparency.
During Lechleiter’s mandate, IFPMA has launched a number of partnerships, such as those targeting non-communicable diseases with the PAHO Foundation (the philanthropic arm of the Pan American Health Organization), the International Federation of the Red Cross, and the Consensus Framework for Ethical Collaboration with patients and health-professions organizations. Under Lechleiter IFPMA was amid among the founding partners of the “Fight the Fakes” campaign, a global effort for combating counterfeit medicines that today has 27 members.